Pseudomyxoma Peritonei

A peritoneal adenocarcinoma characterized by build-up of MUCUS in the PERITONEAL CAVITY. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low-grade mucinous neoplasm of the APPENDIX (NCI Thesaurus).

Also Known As:

Networked: 577 relevant articles (45 outcomes, 39 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Mesothelioma
2.	Ascites
3.	Appendiceal Neoplasms (Appendix Cancer)
4.	Neoplasms (Cancer)
5.	Neoplasm Metastasis (Metastasis)

Experts

1.	Morris, David L: 26 articles (05/2022 - 04/2009)
2.	Chua, Terence C: 17 articles (01/2017 - 04/2009)
3.	Sugarbaker, Paul H: 14 articles (09/2021 - 04/2004)
4.	Deraco, Marcello: 14 articles (01/2021 - 09/2002)
5.	Baratti, Dario: 13 articles (01/2021 - 04/2004)
6.	Kusamura, Shigeki: 13 articles (01/2021 - 09/2002)
7.	Sugarbaker, P H: 12 articles (06/2017 - 04/2000)
8.	Liauw, Winston: 12 articles (01/2017 - 02/2010)
9.	Glehen, Olivier: 10 articles (01/2021 - 07/2005)
10.	Glehen, O: 10 articles (06/2020 - 01/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pseudomyxoma Peritonei:

1.	MucinsIBA 01/01/2021 - "Three studies demonstrated that acellular mucin had a better prognosis than low-grade pseudomyxoma peritonei in the PSOGI classification or M1bG1 in the eighth edition of the AJCC classification. " 09/01/2002 - "Our study specifically investigated MUC2 and MUC5AC because these two mucins possessed the physicochemical property of being gel-forming, a property exhibited by pseudomyxoma peritonei grossly. " 10/01/2023 - "Pseudomyxoma peritonei (PMP) is a rare clinical condition of progressive peritoneal mucin accumulation. " 06/12/2023 - "Notably, Pseudomonas plecoglossicida, a species not previously reported in the human microbiome, was found to be the most abundant organism in the mucin of pseudomyxoma peritonei. " 06/12/2023 - "Pseudomyxoma peritonei (PMP) is a rare malignant growth characterized by the production of mucin and the potential for peritoneal relapse. "
2.	Expectorants (Mucolytics)IBA 03/01/1995 - "Pseudomyxoma peritonei: does a true mucolytic agent exist? " 11/01/1986 - "Biochemical identification of the mucus of pseudomyxoma peritonei as the basis for mucolytic treatment." 10/01/2012 - "Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei." 01/01/2008 - "Pseudomyxoma peritonei (PMP) is a rare disease, presenting with large amounts of mucinous ascites, and treatment with intraperitoneal irrigation with mucolytic agents has been tried. " 06/01/2017 - "Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study."
3.	Fluorouracil (Carac)FDA LinkGeneric 01/01/1993 - "Intraperitoneal 5-FU appears to be effective in pseudomyxoma peritonei. " 01/01/1993 - "Pseudomyxoma peritonei: treatment with intraperitoneal 5-fluorouracil." 10/01/1999 - "Given the results above, intraperitoneal administrations of this combined CDDP, 5-FU, MMC therapy may be effective for patients with pseudomyxoma peritonei." 10/01/1999 - "Herein, we report five cases of pseudomyxoma peritonei that responded to a combined postsurgical therapy consisting of CDDP, 5-FU and MMC. " 10/01/1999 - "[Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei]."
4.	Cisplatin (Platino)FDA LinkGeneric 11/01/2007 - "We examined five cases of pseudomyxoma peritonei with treatments of cytoreduction surgery, abdominal lavage and intraperiotoneal administration of cisplatin (CDDP). " 07/01/1998 - "[Three cases of Pseudomyxoma peritonei treated with intraperitoneal inoculation of cisplatin through an implantable port system]." 12/01/1995 - "Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin." 10/20/1989 - "Twelve cases of pseudomyxoma peritonei in the Department of Obstetrics and Gynecology in Kurume University School of Medicine were categorized in three groups by treatment; 3 cases with just operations, 6 cases with chemotherapies after operations and 3 cases with chemotherapies and intraperitoneal inoculations of cisplatin after washing with dextran. " 10/20/1989 - "We confirm the treatment of the intraperitoneal inoculation of cisplatin after dextrose washing with the cytoreductive surgery is one of the most effective therapies for pseudomyxoma peritonei."
5.	Doxorubicin (Adriamycin)FDA LinkGeneric 10/01/1985 - "This is the first case of pseudomyxoma peritonei secondary to an ovarian primary possibly cured by systemic cis-platinum, doxorubicin, and cyclophosphamide." 10/01/1985 - "Successful treatment of pseudomyxoma peritonei of ovarian origin with cis-platinum, doxorubicin, and cyclophosphamide." 12/01/2014 - "•This is the first report of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a woman with pseudomyxoma peritonei.•PIPAC achieved clinical and histological disease remission.•PIPAC with cisplatin and doxorubicin may be effective in pseudomyxoma peritonei. " 12/01/2014 - "Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report." 10/01/2015 - "First evidence in humans with peritoneal cancer from ovarian cancer, gastric cancer, colon cancer, appendiceal cancer, and pseudomyxoma peritonei has been obtained suggesting clinical antitumor activity and procedural safety of repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin. "
6.	Fibrinogen (Factor I)FDA Link 01/01/2020 - "Efficacy of fibrinogen concentrate in major abdominal surgery - A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei." 09/01/2023 - "The FORMA-05 study compared the efficacy and safety of human fibrinogen concentrate (HFC) versus cryoprecipitate for hemostasis in bleeding patients undergoing cytoreductive surgery for pseudomyxoma peritonei (PMP). " 09/01/2023 - "Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study."
7.	Tumor Biomarkers (Tumor Markers)IBA 01/01/2016 - "The serum tumor markers CEA, CA19-9, and CA125 are used to monitor pseudomyxoma peritonei remission, but their expression at tissue level has not been well characterized. " 01/01/2022 - "Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei." 07/01/2013 - "Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei." 08/01/2015 - "The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." 02/19/2023 - "Prognostic Factors in Pseudomyxoma Peritonei with Emphasis on the Predictive Role of Peritoneal Cancer Index and Tumor Markers."
8.	Glucose (Dextrose)FDA LinkGeneric 08/01/1993 - "A patient with malignant pseudomyxoma peritonei underwent a palliative surgical resection and intraperitoneal lavage with 5% dextrose. " 08/01/1981 - "Two patients with pseudomyxoma peritonei (PP) had repeated intraperitoneal washing with 5% dextrose in water. " 08/01/2007 - "[Transient hyperglycemia following intra-peritoneal irrigation with 5% glucose in a patient with pseudomyxoma peritonei]." 05/01/1997 - "Acute hyperglycemia following intraperitoneal irrigation with 10% dextrose in a patient with pseudomyxoma peritonei." 09/01/1984 - "Combined use of intraperitoneal lavage with dextrose 5% and water and an aggressive surgical approach has thus far successfully prevented reaccumulation of pseudomyxoma peritonei originating from bilateral ovarian mucinous cystadenoma associated with multiple peritoneal implants. "
9.	SolutionsIBA 12/01/2019 - "A Modified Low-Cost Technique of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Two Patients: a Solution for Pseudomyxoma Peritonei in the Indian Scenario?" 11/01/1993 - "A case of pseudomyxoma peritonei treated successfully with intraabdominal infusion of a 2.5% solution of dextrose is reported." 06/01/2017 - "Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study."
10.	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 05/15/2012 - "This study examines the potential efficacy of hydrogen peroxide and ascorbic acid in the dissolution of mucinous ascites from pseudomyxoma peritonei. " 05/15/2012 - "Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei." 05/15/2012 - "The mucolytic property of the final mixture (0.2% ascorbic acid/0.2% hydrogen peroxide) was pH-dependent and showed maximal degradation at pH 4.5 and declined as it reached towards neutral pH. The current study introduces the potential applicability of a formulation that holds promise as a mucolytic agent in patients with mucinous ascites from pseudomyxoma peritonei."

Therapies and Procedures

1.	Cytoreduction Surgical Procedures 10/01/2017 - "HIV patient with pseudomyxoma peritonei of extra-appendiceal origin is disease-free and alive 9 years after complete cytoreductive surgery." 01/01/2021 - "This study aimed to report the prognostic predictors and compare the long-term outcomes of complete cytoreductive surgery (CCRS) vs. debulking surgery (DS) in patients with pseudomyxoma peritonei (PMP) of appendiceal origin. " 01/01/2021 - "Complete Cytoreductive Surgery vs. Debulking Surgery for pseudomyxoma peritonei of appendiceal origin: A propensity score-matched study based on a single-center experience." 05/01/2016 - "This study evaluated the role of surgical debulking in improving pseudomyxoma peritonei (PMP)-related symptoms if complete cytoreductive surgery (CCRS) of huge PMP is unachievable. " 10/01/2012 - "The aim of this study was to compare debulking surgery and cytoreductive surgery (CRS) in patients with Pseudomyxoma peritonei (PMP) regarding efficacy and safety. "
2.	Hyperthermic Intraperitoneal Chemotherapy 10/01/2023 - "There is still controversy regarding the best treatment strategy for patients with recurrent pseudomyxoma peritonei (PMP) after CRS and HIPEC. " 03/01/2001 - "These results confirm that extensive surgery combined with HIPEC is feasible in patients with pseudomyxoma peritonei and that improved long-term survival might be achieved." 01/01/2021 - "Studies on the prognostic role of hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei (PMP) are currently not available. " 01/01/2013 - "In this study, hyperthermic intraperitoneal chemotherapy was suitable for 62% of patients with pseudomyxoma peritonei of appendiceal origin." 10/01/2023 - "Es erfolgte eine Recherche und Auswertung der aktuellen Literatur ERGEBNISSE: Für Patienten mit Pseudomyxoma-peritonei(PMP)-Rezidiven nach CRS und HIPEC ist bislang kein Therapiestandard definiert. "
3.	Drug Therapy (Chemotherapy) 01/01/1996 - "The best outcome was achieved with pseudomyxoma peritonei of appendiceal origin with a time interval between surgeries of 2 or more years, a complete cytoreduction, and treatment with intraperitoneal chemotherapy. " 09/01/2007 - "How safe and effective is surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei?" 08/07/2020 - "Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei-A Novel Treatment Approach." 01/01/2021 - "Reply to comments on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei"." 04/01/2020 - "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei."
4.	Therapeutics 09/01/1996 - "Given the above results, intraperitoneal administrations of this combined CDDP-5-FU-MMC therapy may be effective for patients with pseudomyxoma peritonei." 01/01/2022 - "Aim: Pleural dissemination of pseudomyxoma peritonei (PMP) is an extremely rare diagnosis, for which no standard therapy is available.Methods" 01/01/2022 - "The latter condition, widely termed "pseudomyxoma peritonei," tends to pursue a relentless course punctuated by multiple recurrences despite cytoreductive therapy, culminating in death for many patients. " 01/01/2020 - "Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department." 08/01/2009 - "Effective systemic therapy for advanced pseudomyxoma peritonei (PMP) is the focus of investigation. "
5.	Colectomy 02/01/2012 - "Right hemicolectomy is not routinely indicated in pseudomyxoma peritonei." 07/01/2006 - "Right hemicolectomy appears to be the appropriate treatment with aggressive debulking when mucinous cystoadenocarcinoma is associated with pseudomyxoma peritonei. " 10/15/2018 - "Right hemicolectomy was performed, and the pathological examination revealed a mucinous appendiceal adenocarcinoma infiltrating the hepatic flexure without pseudomyxoma peritonei. " 03/01/1992 - "(4) Mucinous cystadenocarcinomas are slowly progressive and are best treated by means of right hemicolectomy with aggressive debulking added if pseudomyxoma peritonei is present. " 01/01/2006 - "Treatment of associated ovarian cystadenocarcinoma and pseudomyxoma peritonei includes right colectomy, bilateral ovariectomy and omentectomy. "